https://orcid.org/0000-0001-8213-6056
References
- Gresham LM, Marzario B, Dutz J, et al. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. J Am Acad Dermatol. 2021;84(6):1652–1666.
- Soy M, Keser G, Atagunduz P, et al. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review. Clin. Rheumatol. 2021;6:898–904.
- Winterfield LS, Menter A, Gordon K, et al. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 2005;64(suppl_2):ii87–ii90.
- Rondaan C, Furer V, Heijstek MW, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019;5(2):e001035.
- Medina-Pestana J, Cristelli MP, Viana LA, et al. Clinical impact, reactogenicity, and immunogenicity after the first CoronaVac dose in kidney transplant recipients. Transplantation. 2022;106(1):e95–e97.
- Karacin C, Eren T, Zeynelgil E, et al. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncol. 2021;17(33):4447–4456.
- Deepak P, Kim W, Paley MA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. 2021.
- Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021;80(10):1306–1311.
- Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884–1893.
- Wong S-Y, Dixon R, Pazos VM, et al. Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies. Gastroenterology. 2021;2:715–718.e4.
- Michiels Y, Houhou-Fidouh N, Collin G, et al. Impact of low-dose methotrexate-adalimumab combination therapy on the antibody response induced by the mRNA-1273 SARS-CoV-2 vaccine: case of an elderly patient with rheumatoid arthritis. Vaccines (Basel). 2021;9(8):883.
- Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021;27(10):1744–1751.
- Seyahi E, Bakhdiyarli G, Oztas M, et al. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. Rheumatol Int. 2021;41(8):1429–1440.
- Seree-Aphinan C, Chanprapaph K, Rattanakaemakorn P, et al. Inactivated COVID-19 vaccine induces a low humoral immune response in a subset of dermatological patients receiving immunosuppressants. Front Med (Lausanne). 2021;8:769845.
- Galbraith MD, Kinning KT, Sullivan KD, et al. Seroconversion stages COVID19 into distinct pathophysiological states. Elife. 2021;10:e65508.
- Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, et al. Antibody responses in COVID-19: a review. Front Immunol. 2021;12:633184.